Jeremy Presley, MD
Family Medicine · Dodge City, KSNPI 1568667798
Payments from drug & device makers
Across 421 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Lilly USA, LLC$766
- AbbVie$490
- Merck$252
- Pfizer$248
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,501100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 59 | $1,524 |
| Novo Nordisk | 86 | $1,062 |
| Lilly USA, LLC | 63 | $766 |
| AbbVie(2 entities) | 35 | $490 |
| Merck | 18 | $252 |
| Pfizer | 17 | $248 |
| Johnson & Johnson | 19 | $231 |
| Abbott | 14 | $196 |
| Sanofi-aventis U.S. LLC | 12 | $186 |
| Electromed, Inc. | 11 | $170 |
| Amgen | 10 | $153 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $142 |
| Dexcom, Inc. | 6 | $126 |
| Novartis | 8 | $126 |
| Sumitomo Pharma America, Inc. | 6 | $119 |
| Bayer | 5 | $73 |
| Amarin Pharma, Inc. | 3 | $71 |
| Exact Sciences | 5 | $70 |
| Sunovion Pharmaceuticals Inc. | 7 | $67 |
| Grifols USA, LLC | 3 | $67 |
| GSK | 4 | $65 |
| Boehringer Ingelheim | 3 | $52 |
| Eisai Inc. | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Roche Diagnostics Corporation | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Medtronic | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$714
- BREZTRI$580
- AIRSUPRA$477
- SYMBICORT$135
- BREZTRI AEROSPHERE$135
How this compares
$6,507 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 150 | $146,459 |
| EliquisApixaban | 217 | $116,116 |
| XareltoRivaroxaban | 93 | $74,658 |
| JardianceEmpagliflozin | 109 | $52,460 |
| FarxigaDapagliflozin Propanediol | 84 | $51,830 |
| RybelsusSemaglutide | 25 | $39,357 |
| Xigduo XrDapaglifloz Propaned/Metformin | 33 | $32,132 |
| TrulicityDulaglutide | 23 | $31,206 |
| GemtesaVibegron | 58 | $26,321 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $25,071 |
| MyrbetriqMirabegron | 61 | $22,624 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $22,457 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $20,796 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $14,855 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $14,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,062 | $185,816175 claims |
| PfizerEliquis, Abrysvo | $248 | $129,528262 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $1,524 | $86,916155 claims |
| Johnson & JohnsonXarelto | $231 | $74,65893 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat | $52 | $72,709143 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $766 | $44,17437 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $65 | $36,827103 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $119 | $26,32158 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Dodge City
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.